Company Overview
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +80.86% |
| 6 Months: | +264.84% |
| 3 Months: | +137.52% |
| 1 Month: | +21.61% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)72.82 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TTRX Turn Therapeutics Inc. PHARMA | 12.66 | -45.21 | $384.46M | 0.00% | -29.18% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | - | 0 | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | - | 1.37M | - | - |
| Operating Income | -672.99K | - | -1.37M | - | - |
| EBITDA | - | - | -1.37M | - | - |
| Interest Expense | - | - | - | - | - |
| Pretax Income | - | - | -1.24M | - | - |
| Tax Provision | - | - | - | - | - |
| Net Income | -666.44K | - | -1.24M | - | - |
| Diluted EPS | -0.03 | -0.01 | -0.04 | -0.06 | -0.03 |
| R&D Expense | 153.28K | 9.26K | - | 158.70K | 109.43K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | - |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 2.31M | 1.80M | - |
| Operating Income | -2.31M | -1.80M | - |
| EBITDA | -2.26M | -1.75M | - |
| Interest Expense | - | - | - |
| Pretax Income | -2.29M | -1.77M | - |
| Tax Provision | - | - | - |
| Net Income | -2.29M | -1.77M | - |
| Diluted EPS | -0.08 | -0.06 | -0.12 |
| R&D Expense | - | 245.96K | 265.57K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 2.01M | 2.05M | 12.16M |
| Current Assets | 1.20M | 1.10M | - |
| Cash & Equivalents | 1.18M | 872.60K | 4.03M |
| Inventory | - | - | - |
| Receivables | - | - | - |
| Total Liabilities | 1.93M | 2.23M | 7.48M |
| Current Liabilities | 489.78K | 707.93K | 6.00M |
| Long Term Debt | - | - | - |
| Total Debt | 25.16K | 121.04K | - |
| Total Equity | 85.77K | -177.43K | 4.69M |
| Shares Outstanding | - | - | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -1.38M | -1.36M | -2.56M |
| Investing Cash Flow | -44.31K | -99.47K | -152.99K |
| Financing Cash Flow | 500.00K | 1.15M | 6.92M |
| Capital Expenditure | -44.31K | -99.47K | - |
| Free Cash Flow | -1.42M | -1.46M | - |
| Net Change in Cash | -921.99K | -308.40K | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | - | - | - |
| Net Margin % | - | - | - |
| ROE % | -2,672.6% | 996.7% | - |
| ROCE % | -151.5% | -134.0% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | SteelPeak Wealth, LLC | 0.84% | 249.46K | $3.73M |
| 2 | IEQ Capital, LLC | 0.76% | 227.40K | $3.40M |
| 3 | Ddfg, Inc | 0.36% | 107.83K | $1.61M |
| 4 | Vanguard Capital Management LLC | 0.25% | 74.30K | $1.11M |
| 5 | Wellington Shields & Co., LLC | 0.22% | 65.73K | $982.04K |
| 6 | Millennium Management Llc | 0.20% | 60.55K | $904.63K |
| 7 | Blackrock Inc. | 0.13% | 38.59K | $576.55K |
| 8 | Aaron Wealth Advisors LLC | 0.11% | 32.56K | $486.51K |
| 9 | Tamar Securities, LLC | 0.10% | 30.00K | $448.20K |
| 10 | Royal Bank of Canada | 0.09% | 28.25K | $422.05K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TTRX
TTRX - Finviz
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE5KN19VQU5LajVXYkQ3eGhPeGoxb24wUDJxbUdPNmVUUGxrcFNtYjFwdlhjY3V5eENfOTRIWjVqTjRTa2U0ZFlDN2RsNEFaRVJDZ1Z6Z21kTnIwTTlySVU5bQ?oc=5" target="_blank">TTRX</a> <font color="#6f6…
Turn Therapeutics (NASDAQ:TTRX) Rating Lowered to Sell at Wall Street Zen - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNVzBJMUR1TU9YTjF3WEoyWV9DU1VEbFUyQ1dkWWMtemw0NFhZVVg1RWhXd2JjWHFTVEZzN0Q4ODY3WGY1TjRlbGZsQUVETFR0MW9iVDZ3Xzd6N2plQXZ0d2I1YkNLSVF2Zl9CT083Y0IwVnBzUUZUQUZyY0p0UW9uNDRhcnNtc2hCMHlGdl…
Turn Therapeutics broadens GX-03 trial after interim data in dermatitis - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOY0FjY2N1ZmNDeUZ0eUJ0LW1GTkh4NEF2V3dKbVhwbW94Q0JQNmVMOWpUcGpqX0dqSW9YZnRlUy13dkFVNXFBSkFOMGZQbzFGWTh1ZkR5TXhwakV0M00za08tRl9NN1lKSFJwbUNlSXBlcGRzQmlIVk0wdW9fVFc1cEViSG9LbGNsN3VwdT…
TTRX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9UbjlfZzdQeG5kQWNLRmZLZjZwYkp6dmRHcXF3LWp5RWtFR1FKU2RvdUhVSDRLVktOLUE3SllKeFlERDVFVmQxUl9WOTJqcU9WRlhhWTk3UmpDSS1zQm1xUzE0Um9xLXFxcktLQmJJQ0p4RU1QZjVLYUpR?oc=5" target="_blank">TTR…
Turn Therapeutics stock rises on expanded dermatitis trial - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNV2NfZllkbXpyQ0pzbk1YSm1XQS1lb2JjSG1obENWY3NGZndvN0xwM3FjOERzWFNGQjlYclJUMHhkWTVNSzR6Q21lZUdFZG8xY2VBbFRUXzh2VWw5RlA3N1ZpNkZtdlBKZm5DU3JtZm5ZZXZZOTB5YlJDNGdGMElZU0pIWnl1M1BuM2NTSz…
Turn Therapeutics: Small Market Cap, Huge Potential (NASDAQ:TTRX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOOUkzTVFuaktDMkdSdnJtX2F1WlFBakh5Y3dtQk4xQVhXUkFWdkFGTW5qWHRZeE1SY2xuSXhjRGdaNWtiamhQRFBjMjhXVzMxMlFid1F3TTZxblc1UGI0RTlGdGY2NzJnYnpUek5GNEtCMHA2S0RtRzVLdEFmc2lOa0lxWTdxU0ZiZnVhZD…
TTRX — Frequently Asked Questions
What is the current share price of Turn Therapeutics Inc. (TTRX)?
As of 2026-09-19 21:16 PDT, Turn Therapeutics Inc. (TTRX) trades at $12.66 on NasdaqGM. Its 52-week range is $2.71 to $12.66.
What is the market capitalisation of TTRX?
Turn Therapeutics Inc. (TTRX) has a market capitalisation of $384.46M on NasdaqGM.
What is the P/E ratio of TTRX?
TTRX trades at a trailing price-to-earnings (P/E) ratio of -45.21. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 649.57.
Is TTRX a good stock to buy?
This page provides a data-driven analysis of Turn Therapeutics Inc. (TTRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.